South Korean biopharma company Celltrion is planning on filing for US regulatory approval for 2 biosimilars by June 2017. This includes its oncology biosimilar drug rituximab (Truxima), biosimilar to Rituxan, and trastuzumab (Herzuma), biosimilar to Herceptin. Both reference biologics are manufactured by Roche.
Truxima would potentially be indicated for the treatment of non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis (RA), Wegener granulomatosis, and microscopic polyangiitis. Truxima is already approved in the European Union (EU). Celltrion is also awaiting approval of Herzuma in the EU after making its filing in October 2016.
Once approved by FDA, the drugs would be marketed via Celltrion’s US marketing and sales partner Teva Pharmaceutical Industries. Celltrion already has 1 biosimilar approved for marketing in the US—Remsima, an infliximab biosimilar of Johnson & Johnson’s Remicade—that is already being sold via partner Pfizer at a 15% discount to the Johnson & Johnson drug.
Celltrion commented that the company plans to quickly drive up their market share in each country to fend off rivals while continuing to raise their reputation in the medical community by accumulating robust prescription data proving the safety and efficacy of their products.
Currently, the FDA has approved 5 biosimilar products, 4 of which are treatments for immune/inflammatory diseases including RA. The other approved biosimilar is Zarxio (filgrastim-sndz), Sandoz’s biosimilar to Amgen’s granulocyte colony-stimulating factor (G-CSF) Neupogen, approved to boost white cell counts after chemotherapy. Truxima and Herzuma would be among the first non-G-CSF oncology biosimilars if approved by the FDA.
The patents of Herceptin and Avastin are expected to retire in 2019. According to some predictions, at least 4 more biosimilars may gain US approval on first-cycle review. (There are some previously rejected applications that may be resubmitted for review). The potential new products include:
Herceptin and Avastin are both blockbuster cancer treatments. Herceptin is indicated for the treatment of breast cancer and stomach cancer; Avastin is indicated for glioblastoma, metastatic colorectal cancer, non-small cell lung cancer, metastatic kidney cancer, advanced cervical cancer, and platinum-resistant ovarian cancer.
Biosimilar Substitution Can Reduce TCOC, Improve Provider Performance in Value-Based Payment Models
December 7th 2023A simulation study estimated the impact of biosimilar substitution on total cost of care (TCOC) and provider financial performance in the final performance period of the Oncology Care Model.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Biosimilars Regulatory Roundup for September 2023—Podcast Edition
October 1st 2023On this episode, we discuss several regulatory updates from around the globe, including some European and Japanese approvals, the FDA’s 2-day workshop on the present science behind clinical efficacy testing for biosimilars, and streamlining biosimilar development.
IQVIA Highlights Opportunity to Cash In on Biosimilars for Biologics Losing Market Exclusivity
November 29th 2023A report from IQVIA noted that Europe could miss out on €15 billion in cost savings by not having biosimilars for medications about to lose market exclusivity, shedding light on the implications for overall health care savings and ultimately, patient access.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.